New legislation could make it easier for people to participate in clinical trials regardless of their economic situation.
Nearly 1.7 million Americans learned they had cancer in 2017. Most of these patients began traditional treatments like chemotherapy, radiation and surgery. Yet for many, a groundbreaking new immuno-oncology therapy could have been a better alternative.
The need for robust clinical trials participation is critical to women and men across this country, whether they know it or not.
Is precision medicine gaining traction in the field of oncology? The Food and Drug Administration’s recent approval of the cancer drug pembrolizumab offers a hint.
The first anniversary of the White House’s Precision Medicine Initiative gave participants time to reflect on the year’s progress – and contemplate the challenges ahead.